TRB Wealth Management LLC Takes Position in Stryker Corporation $SYK

TRB Wealth Management LLC acquired a new stake in Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,538 shares of the medical technology company’s stock, valued at approximately $484,000.

A number of other hedge funds also recently added to or reduced their stakes in SYK. Gables Capital Management Inc. purchased a new position in Stryker during the 2nd quarter valued at about $25,000. Kilter Group LLC bought a new stake in shares of Stryker in the 2nd quarter valued at about $25,000. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker in the 4th quarter worth approximately $26,000. Sankala Group LLC purchased a new stake in shares of Stryker in the 4th quarter worth approximately $26,000. Finally, United Financial Planning Group LLC bought a new position in shares of Stryker during the third quarter valued at approximately $27,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on SYK shares. The Goldman Sachs Group reissued a “neutral” rating and set a $361.00 price objective on shares of Stryker in a report on Friday, May 1st. BMO Capital Markets started coverage on Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price for the company. Argus set a $370.00 target price on Stryker in a research report on Thursday, July 9th. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a report on Friday, May 1st. Finally, JPMorgan Chase & Co. reduced their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Stock Up 0.7%

Shares of Stryker stock opened at $329.86 on Friday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The company has a market cap of $126.52 billion, a P/E ratio of 34.18, a PEG ratio of 2.09 and a beta of 0.76. The firm’s 50 day moving average price is $326.99 and its 200-day moving average price is $332.64. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Insider Activity

In other news, Director Ronda E. Stryker sold 50,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 665,370 shares of company stock worth $216,238,501. Insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.